ijms-logo

Journal Browser

Journal Browser

Immunotherapy-Based Combinations in Thoracic Malignancies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 2366

Special Issue Editor


E-Mail Website
Guest Editor
Department of Internal Medicine and Medical Specialties, Università degli Studi di Genova, 16132 Genova, Italy
Interests: lung cancer; immunotherapy; liquid biopsy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

The management of thoracic malignancies has experienced dramatic developments with the advent of immune checkpoint inhibitors (ICIs). While ICIs have been successfully used as single-agent regimens for advanced non-small cell lung cancer (NSCLC), approaches involving their use in combination are widely employed nowadays. The addition of an anti-PD-1/PD-L1 agent to chemotherapy improved outcomes over chemotherapy alone, both in NSCLC and in small cell lung cancer (SCLC), irrespective of acknowledged biomarkers, such as PD-L1 expression. Similarly, ICI-based combinations including agents active against multiple checkpoints, such as PD-1/PD-L1 and CTLA-4, are effective in NSCLC and in pleural mesothelioma. While most data are available for metastatic disease, locally advanced disease and localized NSCLC will also benefit from regimens containing immunotherapy concurrently or in sequence with chemotherapy.

The advances in the use of ICI-based combinations for multiple settings in thoracic malignancies leaves room for discussion on relevant topics, such as the management of immune-related toxicities (which cause particular concern in non-metastatic settings) and the identification of more robust response predictors.

This special issue explores the evolving role of ICI-based combinations in thoracic malignancies, with considerations including, but not limited to, immune-related adverse events and predictions of responses.

Prof. Dr. Carlo Genova
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-small cell lung cancer
  • small cell lung cancer
  • malignant pleural mesothelioma
  • immune checkpoint inhibitor
  • immune-related adverse events
  • PD-L1
  • PD-1
  • CTLA-4

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 281 KiB  
Review
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies
by Lauren Chiec and Debora S. Bruno
Int. J. Mol. Sci. 2024, 25(19), 10861; https://doi.org/10.3390/ijms251910861 - 9 Oct 2024
Cited by 1 | Viewed by 1968
Abstract
Pleural mesothelioma is a rare malignancy associated with asbestos exposure and very poor prognosis, with a 5-year overall survival of 12%. Outcomes may vary according to stage at time of diagnosis and histologic subtype. Most recently, clinical trials utilizing dual checkpoint inhibitor regimens [...] Read more.
Pleural mesothelioma is a rare malignancy associated with asbestos exposure and very poor prognosis, with a 5-year overall survival of 12%. Outcomes may vary according to stage at time of diagnosis and histologic subtype. Most recently, clinical trials utilizing dual checkpoint inhibitor regimens and chemotherapy in combination with immune oncologic agents have demonstrated impactful changes in outcomes. In this article, we review studies that have led to the successful implementation of immunotherapy in clinical practice for the treatment of this disease and highlight ongoing clinical trials exploring the use of different immunotherapy strategies for the treatment of pleural mesothelioma. We also discuss the challenges of immunotherapy-based approaches in the context of mesothelioma and future strategies currently being investigated to overcome them. Full article
(This article belongs to the Special Issue Immunotherapy-Based Combinations in Thoracic Malignancies)
Back to TopTop